Package Leaflet: Information for the Patient
AKANTIOR 0.8 mg/ml eye drops, solution in single-dose container
polyhexanide
Read the entire package leaflet carefully before starting to use this medicine, as it contains important information for you.
Contents of the package leaflet
AKANTIOR contains the active substance polyhexanide.
AKANTIOR is used in adults and children from 12 years of age to treat Acanthamoeba keratitis. Acanthamoeba is a parasite (a tiny organism that lives inside humans and can cause disease) that can cause an infection leading to keratitis (inflammation of the cornea, the transparent layer on the front of the eye). Acanthamoeba keratitis can cause serious defects in the corneal surface, including ulcers (open sores).
AKANTIOR damages the membrane (outer skin) of the Acanthamoeba parasite and causes the release of cellular contents, which destroys the cell. AKANTIOR also prevents the Acanthamoeba parasite from making copies of its DNA by interfering with enzymes (proteins) responsible for the replication process, which disrupts the growth and reproduction of the parasite in humans.
Do not use AKANTIOR
If you are allergic to polyhexanide or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before starting to use AKANTIOR.
Treatment with AKANTIOR may cause mild to moderate eye discomfort (such as eye pain) and red eye. If you experience a severe eye reaction, contact your doctor.
Children and adolescents
AKANTIOR is not recommended for use in children under 12 years of age, as it has not been studied in this age group.
Other medicines and AKANTIOR
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
If you are using another eye drop,wait at least 5 minutes between applying AKANTIOR and applying the other eye drop. AKANTIOR should be applied last.
Pregnancy and breastfeeding
There is no experience with the use of AKANTIOR in pregnant women. AKANTIOR should not be used during pregnancy. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
It is not known whether AKANTIOR is excreted in breast milk. Ask your doctor or pharmacist for advice before starting treatment with AKANTIOR.
Driving and using machines
Your vision may be temporarily blurred after using AKANTIOR. Do not drive or use machines until your vision is clear again.
AKANTIOR contains phosphates
This medicine contains 0.37 mg of phosphates in each drop, equivalent to 10.66 mg/ml. If you have severe damage to the transparent layer on the front of the eye (cornea), treatment with phosphates may, in very rare cases, cause cloudy patches on the cornea due to calcium.
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, talk to your doctor again.
The treatment consists of two parts: intensive treatment for the first 19 days and continuation treatment from day 20.
The recommended dose is 1 dropof AKANTIOR in the affected eye as follows:
Initial intensive treatment (19 days)
Continuation treatment
Your doctor will tell you when to stop treatment.
Instructions for use
If you use more AKANTIOR than you should
Apply the next dose at the usual time, as it is unlikely to cause serious harm.
If you forget to use AKANTIOR
Apply the next dose at the usual time. Do not use a double dose to make up for forgotten doses.
If you stop using AKANTIOR
Use AKANTIOR as your doctor has told you to get the most benefit. Always talk to your doctor if you think you want to stop treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most side effects are mild and temporary.
See your doctorif you have a severe eye reaction.
The following side effects have been reported:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date is the last day of the month shown on the unopened product.
This medicine does not require any special storage conditions.
After opening the pouch, the single-dose containers must be used within 28 days. After this period, unused single-dose containers should be discarded.
The contents of the single-dose container should be used immediately after opening the container, and any remaining contents should be discarded.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of AKANTIOR
AKANTIOR contains phosphates (see section 2).
Appearance and packaging of the product
AKANTIOR eye drops, solution in single-dose container (eye drops) is a clear, colorless solution in a single-dose container.
The single-dose containers are packaged in sealed strips of 5 units, which are included in a polyester/aluminum/polyethylene pouch and packaged in a box.
Container sizes:
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
SIFI S.p.A.
Via Ercole Patti, 36
95025 Aci Sant'Antonio (CT)
Italy
Date of last revision of this package leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
You can access detailed and up-to-date information about this medicine by scanning the QR code included in the package leaflet and on the box with your smartphone or device. You can also access this information at the following internet address: https://qr.sifigroup.com/akantior/.
[QR code]